AstraZeneca shares sink 8% after $39 billion Alexion buyout

This post was originally published on this site

Chief Executive Officer Pascal Soriot had told reporters on Saturday that the deal, a bet on rare-disease and immunology drugs, was the result of exclusive talks and no competitive bidder was involved.

The move also helps AstraZeneca, which is also working on a COVID-19 vaccine, diversify from its fast-growing cancer business.

Add Comment